SERPINA1 and alpha 1-antitrypsin deficiency: Indeed, a previous study demonstrated that more than 85% of AATD patients still experience COPD exacerbations, despite the protective serum AAT levels being reached by the augmentation therapy, suggesting the need for a more aggressive care for the most symptomatic subjects [32].